lomustine has been researched along with Cancer of Colon in 47 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Every third patient with colon cancer Dukes' C and every fourth patient with rectal cancer Dukes' C survives 5 years." | 2.65 | [Background and experience of adjuvant cytostatic therapy in gastrointestinal cancer (author's transl)]. ( Bengmark, S; Eriksson, S; Hafström, L; Hugander, A, 1981) |
| "Forty-six adult patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds." | 2.64 | Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil. ( Bedikian, AY; Bodey, GP; Burgess, MA; Livingston, R; Staab, R; Valdivieso, M, 1978) |
| "Among patients with resected colon cancer, black patients have worse survival than whites." | 2.47 | Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. ( Benedetti, JK; Blackstock, AW; Dignam, JJ; Goldberg, RM; O'Connell, MJ; Saltz, LB; Sargent, DJ; Wolmark, N; Yothers, G, 2011) |
| "At the current time, patients with colon cancer of Dukes stage C should be offered adjuvant chemotherapy with 5-FU/levamisole outside of clinical studies." | 1.29 | [Adjuvant treatment of colonic carcinoma]. ( Herrmann, R; Rochlitz, CF, 1995) |
| " The exposure to O6-alkylguanines gave a greater enhancement of the toxic effects of ClEtSoSo than of CCNU." | 1.27 | Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. ( Dolan, ME; Pegg, AE; Young, GS, 1986) |
| "Eighteen adult colorectal cancer patients, previously untreated with systemic chemotherapy, were given CCNU and MISO." | 1.27 | Evaluation of CCNU and misonidazole in the treatment of advanced colorectal cancer. ( Anagnost, J; Bennett, JM; Boros, L; Mulcahy, RT; Siemann, DW; Sutherland, RM, 1987) |
| "One patient with gastric cancer attained a partial remission with a duration of remission of 9." | 1.26 | [Clinical and therapeutic study (phase II) using VP-16/213 and methyl-CCNU in patients with inoperable, recurring or metastasizing carcinomas of the gastriointestinal tract]. ( Hartmann, D; Obrecht, JP; Stalder, GA, 1978) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (93.62) | 18.7374 |
| 1990's | 2 (4.26) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (2.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yothers, G | 1 |
| Sargent, DJ | 1 |
| Wolmark, N | 1 |
| Goldberg, RM | 1 |
| O'Connell, MJ | 1 |
| Benedetti, JK | 1 |
| Saltz, LB | 1 |
| Dignam, JJ | 1 |
| Blackstock, AW | 1 |
| Queisser, W | 1 |
| Heim, ME | 1 |
| Zannini, G | 1 |
| Contieri, E | 1 |
| Xavier, AM | 1 |
| Kasimis, BS | 1 |
| Wu, SY | 1 |
| Kaneshiro, CA | 1 |
| Higgins, GA | 1 |
| Gisselbrecht, C | 1 |
| Belpomme, D | 1 |
| Mignot, L | 1 |
| Marty, M | 1 |
| Mathé, G | 1 |
| Boiron, M | 1 |
| White, DR | 1 |
| Richards, F | 1 |
| Muss, HB | 1 |
| Cooper, MR | 1 |
| Spurr, CL | 1 |
| Bonomi, PD | 1 |
| Chandra, G | 1 |
| Rossof, AH | 1 |
| Klaassen, D | 2 |
| Vaughn, CB | 1 |
| Chapman, JL | 1 |
| Garland, M | 1 |
| Pederson, B | 1 |
| Demitrish, MM | 1 |
| Chinn, B | 1 |
| Ward, D | 1 |
| Brady, PR | 1 |
| Hafström, L | 1 |
| Bengmark, S | 1 |
| Eriksson, S | 1 |
| Hugander, A | 1 |
| Seifart, W | 1 |
| Marx, G | 1 |
| Gagliano, RG | 1 |
| Panettiere, FJ | 1 |
| Haas, CD | 1 |
| Baker, L | 1 |
| Hewlett, J | 1 |
| Stuckey, WJ | 1 |
| O'Bryan, RM | 1 |
| Bottomley, R | 1 |
| Heilburn, LK | 1 |
| Gamucci, T | 1 |
| Zampa, G | 1 |
| Rochlitz, CF | 1 |
| Herrmann, R | 1 |
| Barrett, A | 1 |
| Gazet, JC | 1 |
| Bradbeer, JW | 1 |
| Peckham, MJ | 1 |
| Hartwich, G | 1 |
| Neidhardt, B | 1 |
| Hossfeld, DK | 1 |
| Osieka, R | 1 |
| Houchens, DP | 1 |
| Goldin, A | 1 |
| Johnson, RK | 1 |
| Moertel, CG | 5 |
| Pratt, CB | 1 |
| Rivera, G | 1 |
| Shanks, E | 1 |
| Johnson, WW | 1 |
| Howarth, C | 1 |
| Terrell, W | 1 |
| Kumar, AP | 1 |
| Valdivieso, M | 2 |
| Bedikian, A | 1 |
| Burgess, MA | 2 |
| Rodriguez, V | 1 |
| Hersh, EM | 1 |
| Bodey, GP | 2 |
| Mavligit, GM | 1 |
| Bedikian, AY | 1 |
| Staab, R | 1 |
| Livingston, R | 1 |
| Hartmann, D | 1 |
| Obrecht, JP | 1 |
| Stalder, GA | 1 |
| Drewinko, B | 1 |
| Barlogie, B | 1 |
| Freireich, EJ | 1 |
| Corbett, TH | 1 |
| Griswold, DP | 1 |
| Wolpert, MK | 1 |
| Venditti, JM | 1 |
| Schabel, FM | 2 |
| Bolton, PM | 1 |
| Pouillart, P | 1 |
| Palangie, T | 1 |
| Jouve, M | 1 |
| Langlois, A | 1 |
| Garcia-Giralt, E | 1 |
| Regensberg, C | 1 |
| Blic, V | 1 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Gautier, H | 1 |
| Baron, A | 1 |
| Cedermark, BJ | 1 |
| Didolkar, MS | 1 |
| Elias, EG | 1 |
| Douglass, HO | 2 |
| Lavin, PT | 1 |
| Hill, GJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, WL | 1 |
| Davis, HL | 1 |
| Grage, T | 1 |
| Fletcher, WS | 1 |
| Golomb, FM | 1 |
| Cruz, AB | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Carter, SK | 2 |
| Mitchell, RB | 1 |
| Moschel, RC | 1 |
| Dolan, ME | 3 |
| Larkin, GL | 1 |
| English, HF | 1 |
| Pegg, AE | 2 |
| Marangolo, M | 1 |
| Pezzuoli, G | 1 |
| Marubini, E | 1 |
| Amadori, D | 1 |
| Boracchi, P | 1 |
| Cocconi, G | 1 |
| Cunsolo, A | 1 |
| Garcea, D | 1 |
| Germiniani, R | 1 |
| Luporini, G | 1 |
| MacIntyre, JM | 1 |
| Kaufman, J | 1 |
| Von Hoff, D | 1 |
| Engstrom, PF | 1 |
| Young, GS | 1 |
| Schaefer, EL | 1 |
| Morimoto, RI | 1 |
| Theodorakis, NG | 1 |
| Seidenfeld, J | 1 |
| Anagnost, J | 1 |
| Bennett, JM | 1 |
| Sutherland, RM | 1 |
| Boros, L | 1 |
| Siemann, DW | 1 |
| Mulcahy, RT | 1 |
| Presant, CA | 1 |
| Kennedy, P | 1 |
| Wiseman, C | 1 |
| Gala, K | 1 |
| Smith, JD | 1 |
| Bouzaglou, A | 1 |
| Farbstein, M | 1 |
| Multhauf, P | 1 |
| Bertrand, M | 1 |
| Green, L | 1 |
| Platinskiĭ, LV | 1 |
| Sokolova, VD | 1 |
| Ozhiganov, EL | 1 |
| Workman, P | 1 |
| Morgan, JE | 1 |
| Talbot, K | 1 |
| Wright, KA | 1 |
| Donaldson, J | 1 |
| Twentyman, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon[NCT00425152] | Phase 3 | 2,151 participants (Actual) | Interventional | 1989-07-31 | Completed | ||
| Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole Versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer[NCT00002593] | Phase 3 | 1,135 participants (Actual) | Interventional | 1994-12-31 | Completed | ||
| Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer[NCT00003835] | Phase 3 | 1,260 participants (Anticipated) | Interventional | 1999-05-31 | Completed | ||
| A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931] | Phase 3 | 2,472 participants (Anticipated) | Interventional | 2000-02-29 | Completed | ||
| A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma [NCT00096278] | Phase 3 | 2,710 participants (Actual) | Interventional | 2004-09-15 | Completed | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Where events are defined as recurrence, second primary cancer, or death from any cause (NCT00096278)
Timeframe: 3 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil | 75.5 |
| Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | 77.4 |
Percentage of patients who did not experience an event where events are defined as death from any cause. (NCT00096278)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (mFOLFOX6) | 77.6 |
| Arm II (Bevacizumab, mFOLFOX6) | 78.7 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
6 reviews available for lomustine and Cancer of Colon
| Article | Year |
|---|---|
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemotherapy | 2011 |
Chemotherapy in alimentary tract malignomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Cytarabine; Doxor | 1981 |
Chemotherapy of gastrointestinal cancer.
Topics: Apudoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Hum | 1978 |
Nitrosoureas: a review of experimental antitumor activity.
Topics: Animals; Carmustine; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy, | 1976 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
[Chemotherapy of cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms | 1985 |
11 trials available for lomustine and Cancer of Colon
| Article | Year |
|---|---|
Combination chemotherapy with 5-fluorouracil, CCNU, and vincristine in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide | 1980 |
MItomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; F | 1980 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dru | 1981 |
[Background and experience of adjuvant cytostatic therapy in gastrointestinal cancer (author's transl)].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1981 |
Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Eva | 1978 |
[Non resectable colonic cancer. Results from a test of chemotherapy with simultaneous prescription of VM26, methyl-CCNU and 5 fluoro-uracile (author's transl)].
Topics: Adult; Aged; BCG Vaccine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans | 1978 |
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms; | 1976 |
Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1976 |
Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Results of a multicentric randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1989 |
Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Humans; Lomu | 1985 |
30 other studies available for lomustine and Cancer of Colon
| Article | Year |
|---|---|
[Indications for the Babcock-Bacon operation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colonic Neoplasms; Doxorubicin; Humans; L | 1952 |
[Hormone receptors in colonic cancer].
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Lomustine; Male; Medroxyprogesterone; Prognosis; Re | 1982 |
Adjuvant therapy for carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; L | 1984 |
Chemotherapy of carcinomas of the digestive tract.
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Esop | 1982 |
[Results of surgical and complex treatment of colonic and rectal cancer].
Topics: Colectomy; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Lomustine; Neoplasm Staging; P | 1982 |
Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Colonic Neoplasms; Deoxyguanosine; Drug Evaluation; Drug Therapy, Combination; Human | 1981 |
Cardiotoxicity of 5-fluorouracil.
Topics: Angina Pectoris; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lomusti | 1980 |
[Adjuvant treatment of colonic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1995 |
Failure of methyl-C.C.N.U. and 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1978 |
[Chemotherapy of colorectal carcinomas].
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Palli | 1978 |
[The state of chemotherapy of colorectal neoplasms].
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine | 1978 |
Chemotherapy of human colon cancer xenografts in athymic nude mice.
Topics: Acridines; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma | 1977 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Colorectal carcinoma in adolescents implications regarding etiology.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Child; Colonic Neoplasms; Female; Fluorouracil; Humans; | 1977 |
Chemoimmunotherapy of metastatic large bowel cancer: nonspecific stimulation with BCG and levamisole.
Topics: BCG Vaccine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Levamisole; Lomusti | 1977 |
[Clinical and therapeutic study (phase II) using VP-16/213 and methyl-CCNU in patients with inoperable, recurring or metastasizing carcinomas of the gastriointestinal tract].
Topics: Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Hum | 1978 |
Response of exponentially growing, stationary-phase, and synchronized cultured human colon carcinoma cells to treatment with nitrosourea derivatives.
Topics: Carmustine; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Colonic Neoplasms; Dose-Respo | 1979 |
Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.
Topics: Animals; Antineoplastic Agents; Carmustine; Cisplatin; Colonic Neoplasms; Drug Evaluation, Preclinic | 1979 |
Chemotherapy, immunotherapy and chemoimmunotherapy of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Lomustine; Methotrexate; Mitomycins; Rectal | 1977 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Gastrointestinal cancer. Treatment with fluorouracil-nitrosourea combinations.
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neo | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
Topics: Animals; Carmustine; Colonic Neoplasms; DNA; DNA, Neoplasm; DNA, Single-Stranded; Drug Resistance; D | 1992 |
Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line; Colonic Neoplasms; Dose-Response Relationship, | 1989 |
Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents.
Topics: Carcinoma; Cell Cycle; Cell Line; Cell Survival; Colonic Neoplasms; Humans; Lomustine; Mesylates; Me | 1986 |
Chemical specificity for induction of stress response genes by DNA-damaging drugs in human adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cell Line; Colonic Neoplasms; DNA Damage; Genes; | 1988 |
Evaluation of CCNU and misonidazole in the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1987 |
Pilot phase II trial of amphotericin B and CCNU in renal and colorectal carcinomas.
Topics: Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neopl | 1986 |
CB 1954 revisited. II. Toxicity and antitumour activity.
Topics: Animals; Aziridines; Azirines; Colonic Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug | 1986 |